The pathobiology of pulmonary arterial hypertension (PAH) is complex and is not understood completely (1). Several abnormal signaling pathways have been identified, involving the three layers of the ...
We previously reported on the partial prevention of experimental shunt-induced pulmonary arterial hypertension (PAH) by the nonselective endothelin (ET) ET-A/ET-B receptor antagonist bosentan. As the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback